The N-terminal Arg2, Arg3 and Arg4 of Human Lactoferrin Interact with Sulphated Molecules but Not with the Receptor Present on Jurkat Human Lymphoblastic T-cells
Overview
Affiliations
We previously characterized a 105 kDa receptor for human lactoferrin (hLf) on Jurkat human lymphoblastic T-cells. To delineate the role of the basic cluster Arg2-Arg3-Arg4-Arg5 of hLf in the interaction with Jurkat cells, we isolated N-terminally deleted hLf species of molecular mass 80 kDa lacking two, three or four N-terminal residues (hLf-2N, hLf-3N and hLf-4N) from native hLf that had been treated with trypsin. Native hLf bound to 102000 sites on Jurkat cells with a dissociation constant (Kd) of 70 nM. Consecutive removal of N-terminal arginine residues from hLf progressively increased the binding affinity but decreased the number of binding sites on the cells. A recombinant hLF mutant lacking the first five N-terminal residues (rhLf-5N) bound to 17000 sites with a Kd of 12 nM. The binding parameters of bovine lactoferrin (Lf) and native hLf did not significantly differ, whereas the binding parameters of murine Lf (8000 sites; Kd 30 nM) resembled those of rhLf-5N. Culture of Jurkat cells in the presence of chlorate, which inhibits sulphation, decreased the number of binding sites for both native hLf and hLf-3N but not for rhLf-5N, indicating that the hLf-binding sites include sulphated molecules. We propose that the interaction of hLf with a large number of binding sites (approx. 80000 per cell) on Jurkat cells is dependent on Arg2-Arg3-Arg4, but not on Arg5. Interaction with approx. 20000 binding sites per cell, presumably the hLf receptor, does not require the first N-terminal basic cluster of hLf. Moreover, the affinity of hLf for the latter binding site is enhanced approx. 6-fold after removal of the first basic cluster. Thus N-terminal proteolysis of hLf in vivo might serve to modulate the nature of its binding to cells and thereby its effects on cellular physiology.
Lactoferrin: A Promising Therapeutic Molecule against Human Papillomavirus.
Kaplan M, Baktiroglu M, Kalkan A, Canbolat A, Lombardo M, Raposo A Nutrients. 2024; 16(18).
PMID: 39339673 PMC: 11435110. DOI: 10.3390/nu16183073.
Gori A, Brindisi G, Daglia M, Miraglia Del Giudice M, Dinardo G, Di Minno A Nutrients. 2024; 16(12).
PMID: 38931261 PMC: 11206375. DOI: 10.3390/nu16121906.
Lactoferrins in Their Interactions with Molecular Targets: A Structure-Based Overview.
Piacentini R, Boffi A, Milanetti E Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543184 PMC: 10974892. DOI: 10.3390/ph17030398.
Lactoferrin: from the structure to the functional orchestration of iron homeostasis.
Ianiro G, Rosa L, Bonaccorsi di Patti M, Valenti P, Musci G, Cutone A Biometals. 2022; 36(3):391-416.
PMID: 36214975 DOI: 10.1007/s10534-022-00453-x.
Bukowska-Osko I, Popiel M, Kowalczyk P Int J Mol Sci. 2021; 22(11).
PMID: 34071527 PMC: 8198160. DOI: 10.3390/ijms22115799.